Arcutis Biotherapeutics, Inc.
ARQT
$22.91
$0.673.01%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 261.24% | 117.84% | 69.64% | 29.17% | 83.72% |
| Total Depreciation and Amortization | 79.87% | -55.78% | 2,311.76% | 774.86% | -18.70% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -6.56% | 8.91% | -6.90% | 4.20% | 22.18% |
| Change in Net Operating Assets | -48.44% | -424.29% | 220.18% | -225.01% | -481.27% |
| Cash from Operations | 3,600.67% | 94.94% | 100.72% | 3.87% | 98.67% |
| Capital Expenditure | -- | 100.00% | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -198.00% | -129.73% | 128.17% | 143.06% | 156.09% |
| Cash from Investing | -198.00% | -129.78% | 128.04% | 140.95% | 156.08% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 43.76% | 274.62% | -5.15% | -99.76% | -97.39% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 103.82% | 274.62% | -5.15% | -99.76% | -198.11% |
| Foreign Exchange rate Adjustments | 125.21% | -196.94% | 869.23% | 105.48% | -444.12% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 93.37% | -150.65% | 118.26% | -117.98% | -233.02% |